He Ako Hiringa
Our mission is to contribute to creating equitable access to funded medicines, by providing education and updates to primary care clinicians.
Our resources are free to access. Log in and record your professional development using our CAPTURE function (at the end of each article).
He Ako Hiringa is intended for use by primary care health professionals - it is not a consumer information or education service. Consumers should seek advice from a health professional or visit www.healthnavigator.co.nz.
Our latest content
Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.
Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.
Explore your prescribing further with EPiC Reflect Annual Report. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.
Nirmatrelvir with ritonavir (Paxlovid), a new oral antiviral medicine for adults with COVID-19, is now available for community use. In people at higher risk of severe illness from COVID-19, treatment with Paxlovid has been shown to reduce the incidence of hospitalisation or death. However, for certain patients it will not be safe or appropriate to use Paxlovid. Prescriptions must be endorsed to confirm patients meet Pharmac access criteria.
This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.
Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.
This short video explores what patients think about the move to Amgevita. We spoke to a group of seven New Zealanders living with arthritis to find out how they feel about changing from the biological reference medicine, Humira, to the new biosimilar medicine, Amgevita.
Thirsty for knowledge?
Subscribe to our newsletter to remain up to date with all our content and new features.